

The National Hemophilia Foundation and Affiliate

Consolidated Financial Statements

December 31, 2022

The National Hemophilia Foundation and Affiliate

Consolidated Financial Statements
December 31, 2022

TABLE OF CONTENTS

Page

Independent Auditors' Report

FINANCIAL STATEMENTS

Consolidated Statement of Financial Position	4
Consolidated Statement of Activities	5
Consolidated Statement of Functional Expenses	6
Consolidated Statement of Cash Flows	7
Notes to Consolidated Financial Statements	8

SUPPLEMENTARY INFORMATION

Central Ohio Chapter Statement of Financial Position	24
Central Ohio Chapter Statement of Activities	25
Central Ohio Chapter Statement of Functional Expenses	26
Idaho Chapter Statement of Financial Position	27
Idaho Chapter Statement of Activities	28
Idaho Chapter Statement of Functional Expenses	29
Nevada Chapter Statement of Financial Position	30
Nevada Chapter Statement of Activities	31
Nevada Chapter Statement of Functional Expenses	32
Colorado Chapter Statement of Financial Position	33
Colorado Chapter Statement of Activities	34
Colorado Chapter Statement of Functional Expenses	35
Nebraska Chapter Statement of Financial Position	36
Nebraska Chapter Statement of Activities	37
Nebraska Chapter Statement of Functional Expenses	38
West Virginia Chapter Statement of Financial Position	39
West Virginia Chapter Statement of Activities	40
West Virginia Chapter Statement of Functional Expenses	41
Hawaii Chapter Statement of Financial Position	42
Hawaii Chapter Statement of Activities	43
Hawaii Chapter Statement of Functional Expenses	44

Report on Internal Control Over Financial Reporting and on Compliance and
Other Matters Based on an Audit of Financial Statements Performed in Accordance
With *Government Auditing Standards*

Independent Auditors' Report

**To the Board of Directors of
The National Hemophilia Foundation and Affiliate**

Opinion

We have audited the accompanying consolidated financial statements of The National Hemophilia Foundation and Affiliate, (collectively, the "Foundation") which comprise the consolidated statement of financial position as of December 31, 2022, and the related consolidated statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the consolidated financial statements.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of the Foundation as of December 31, 2022, and the consolidated changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the Foundation and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Change in Accounting Policy

As discussed in Note 2 to the financial statements, The National Hemophilia Foundation and Affiliate adopted Financial Accounting Standards Board ("FASB") Topic 842, *Leases*, which resulted in the recognition of right of use assets and related lease liabilities effective January 1, 2022. Our opinion is not modified with respect to that matter.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Foundation's ability to continue as a going concern within one year after the date that the consolidated financial statements are available to be issued.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards and government auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

In performing an audit in accordance with generally accepted auditing standards and government auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Foundation's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Foundation's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Report on Summarized Comparative Information

We have previously audited The National Hemophilia Foundation and Affiliate's 2021 consolidated financial statements, and we expressed an unmodified audit opinion on those audited financial statements in our report dated June 22, 2022. In our opinion, the summarized comparative information presented herein as of and for the year ended December 31, 2021, is consistent, in all material respects, with the audited financial statements from which it has been derived.

Report on Supplementary Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying supplementary information on pages 24 – 44, as described in the table of contents, is presented for purposes of additional analysis and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated June 16, 2023 on our consideration of the Foundation's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Foundation's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Foundation's internal control over financial reporting and compliance.

PKF O'Connor Davies, LLP

June 16, 2023

The National Hemophilia Foundation and Affiliate

Consolidated Statement of Financial Position December 31, 2022 (With summarized totals at December 31, 2021)

	2022		2021	
	Without Donor Restrictions	With Donor Restrictions	Total	Total
ASSETS				
Cash and cash equivalents	\$ 5,913,349	\$ 6,525,195	\$ 12,438,544	\$ 18,424,427
Government grants receivable	47,925	-	47,925	42,943
Grants and other receivables	544,608	528,256	1,072,864	1,130,185
Contributions receivable	-	60,000	60,000	139,606
Prepaid expenses and other assets	466,345	-	466,345	495,478
Investments	18,132,750	3,143,505	21,276,255	25,542,462
Investments in deferred compensation	351,775	-	351,775	594,746
Security deposits	275,709	-	275,709	276,209
Right-of-use assets, net	1,738,356	-	1,738,356	-
Property and equipment, net	91,573	-	91,573	140,012
	<u>\$ 27,562,390</u>	<u>\$ 10,256,956</u>	<u>\$ 37,819,346</u>	<u>\$ 46,786,068</u>
LIABILITIES AND NET ASSETS				
Liabilities				
Accounts payable	\$ 678,543	\$ -	\$ 678,543	\$ 515,920
Accrued expenses	903,513	-	903,513	484,844
Accrued payroll and vacation	803,697	-	803,697	994,180
Paycheck Protection Program loan	-	-	-	1,541,013
Grants payable	1,545,750	-	1,545,750	1,465,500
Deferred rent	-	-	-	315,423
Deferred support and revenue	128,529	118,053	246,582	13,478
Operating lease liabilities	1,905,769	-	1,905,769	-
Deferred compensation	351,775	-	351,775	594,746
Total Liabilities	<u>6,317,576</u>	<u>118,053</u>	<u>6,435,629</u>	<u>5,925,104</u>
Net Assets				
Without Donor Restrictions				
Undesignated	17,352,814	-	17,352,814	22,468,354
Board-designated	3,892,000	-	3,892,000	5,071,250
Total Net Assets Without Donor Restrictions	<u>21,244,814</u>	<u>-</u>	<u>21,244,814</u>	<u>27,539,604</u>
With Donor Restrictions				
Restricted by purpose or time	-	8,353,592	8,353,592	11,174,975
Endowments	-	1,785,311	1,785,311	2,146,385
Total Net Assets With Donor Restrictions	<u>-</u>	<u>10,138,903</u>	<u>10,138,903</u>	<u>13,321,360</u>
Total Net Assets	<u>21,244,814</u>	<u>10,138,903</u>	<u>31,383,717</u>	<u>40,860,964</u>
	<u>\$ 27,562,390</u>	<u>\$ 10,256,956</u>	<u>\$ 37,819,346</u>	<u>\$ 46,786,068</u>

See notes to consolidated financial statements

The National Hemophilia Foundation and Affiliate

Consolidated Statement of Activities Year Ended December 31, 2022 (With summarized totals for the year ended December 31, 2021)

	2022			2021
	Without Donor Restrictions	With Donor Restrictions	Total	Total
SUPPORT AND REVENUE				
Special events revenue	\$ 371,884	\$ -	\$ 371,884	\$ 736,585
Government grants	447,380	-	447,380	473,734
Contributions and grants	10,843,952	360,538	11,204,490	14,833,452
Contributions from independent chapters	-	48,500	48,500	64,310
Contributions from federal campaign	20,656	-	20,656	17,672
Educational seminars and programs	2,918,748	-	2,918,748	2,014,685
Educational/medical literature	983,649	-	983,649	1,204,908
Legacies and bequests	29,997	350,000	379,997	3,341,911
Paycheck Protection Program loan forgiveness	1,541,013	-	1,541,013	1,398,100
Other income	15,059	-	15,059	1,408
Net assets released from restrictions	3,580,421	(3,580,421)	-	-
Total Support and Revenue	<u>20,752,759</u>	<u>(2,821,383)</u>	<u>17,931,376</u>	<u>24,086,765</u>
OPERATING EXPENSES				
Program Services				
Health education and training	5,899,711	-	5,899,711	4,186,665
Community services	5,029,506	-	5,029,506	4,336,648
Chapter services	2,089,454	-	2,089,454	1,599,021
Research	4,067,409	-	4,067,409	3,020,310
Total Program Services	<u>17,086,080</u>	<u>-</u>	<u>17,086,080</u>	<u>13,142,644</u>
Supporting Services				
Management and general	4,614,543	-	4,614,543	4,552,830
Fundraising	1,501,945	-	1,501,945	1,357,922
Total Supporting Services	<u>6,116,488</u>	<u>-</u>	<u>6,116,488</u>	<u>5,910,752</u>
Total Expenses	<u>23,202,568</u>	<u>-</u>	<u>23,202,568</u>	<u>19,053,396</u>
OTHER (LOSS) INCOME				
Return on investments	(3,844,981)	(361,074)	(4,206,055)	2,507,118
Change in Net Assets	(6,294,790)	(3,182,457)	(9,477,247)	7,540,487
NET ASSETS				
Beginning of year	<u>27,539,604</u>	<u>13,321,360</u>	<u>40,860,964</u>	<u>33,320,477</u>
End of year	<u>\$ 21,244,814</u>	<u>\$ 10,138,903</u>	<u>\$ 31,383,717</u>	<u>\$ 40,860,964</u>

See notes to consolidated financial statements

The National Hemophilia Foundation and Affiliate

Consolidated Statement of Functional Expenses Year Ended December 31, 2022 (With summarized totals for the year ended December 31, 2021)

	Program Services					Supporting Services			2022	2021
	Health Education and Training	Community Services	Chapter Services	Research	Total Program Services	Management and General	Fundraising	Total Supporting Services	Total Expenses	Total Expenses
Salaries	\$ 2,294,001	\$ 1,616,436	\$ 668,823	\$ 1,348,201	\$ 5,927,461	\$ 2,139,336	\$ 650,990	\$ 2,790,326	\$ 8,717,787	\$ 8,038,994
Employee benefits and payroll taxes	516,294	370,956	225,872	253,055	1,366,177	514,958	191,665	706,623	2,072,800	1,957,303
Pension expense	162,375	107,571	58,077	76,973	404,996	175,519	35,187	210,706	615,702	554,241
Total Salaries and Related Expenses	2,972,670	2,094,963	952,772	1,678,229	7,698,634	2,829,813	877,842	3,707,655	11,406,289	10,550,538
Supplies	139,500	69,759	108,345	4,672	322,276	19,819	21,716	41,535	363,811	372,375
Printing and other	117,047	482,168	398	739	600,352	6,104	56,574	62,678	663,030	679,966
Telephone	90,413	17,960	21,887	10,361	140,621	49,678	10,218	59,896	200,517	140,613
Occupancy	174,641	102,395	172,171	52,333	501,540	236,747	57,479	294,226	795,766	768,620
Insurance	15,100	11,602	15,206	4,630	46,538	14,801	5,293	20,094	66,632	60,528
Equipment rental and maintenance	247,621	123,693	84,375	40,031	495,720	106,149	27,677	133,826	629,546	395,588
Travel, conferences and conventions	977,839	529,249	343,512	316,197	2,166,797	254,127	248,083	502,210	2,669,007	749,366
Accounting and auditing	-	-	-	-	-	53,000	-	53,000	53,000	53,123
Consulting and professional fees	802,408	1,153,504	14,624	1,181,760	3,152,296	315,825	34,858	350,683	3,502,979	2,940,045
Legal fees	-	-	-	-	-	544,063	-	544,063	544,063	64,953
Membership dues	181,478	197,441	22,100	70,162	471,181	113,480	108,310	221,790	692,971	548,894
Awards and grants	131,153	215,257	315,383	696,862	1,358,655	17,129	18,500	35,629	1,394,284	1,450,058
Postage and shipping	22,439	20,853	16,722	4,835	64,849	7,408	7,829	15,237	80,086	104,160
Employment recruiting	150	168	-	-	318	17,065	-	17,065	17,383	31,681
Depreciation and amortization	11,836	4,591	11,841	3,528	31,796	12,410	4,233	16,643	48,439	76,663
Banking fees	15,416	5,903	10,118	3,070	34,507	16,925	23,333	40,258	74,765	66,225
Total Expenses	\$ 5,899,711	\$ 5,029,506	\$ 2,089,454	\$ 4,067,409	\$ 17,086,080	\$ 4,614,543	\$ 1,501,945	\$ 6,116,488	\$ 23,202,568	\$ 19,053,396

See notes to consolidated financial statements

The National Hemophilia Foundation and Affiliate

Consolidated Statement of Cash Flows

Year Ended December 31, 2022

(With comparative amounts for the year ended December 31, 2021)

	2022	2021
CASH FLOWS FROM OPERATING ACTIVITIES		
Change in net assets	\$ (9,477,247)	\$ 7,540,487
Adjustments to reconcile change in net assets to net cash from operating activities		
Depreciation and amortization	48,439	76,663
Realized and unrealized losses and (gains) on investments	4,563,049	(1,778,771)
Deferred rent	-	(53,383)
Paycheck Protection Program loan forgiveness	(1,541,013)	(1,398,100)
Amortization of right-of-use assets	646,324	-
Changes in operating assets and liabilities		
Government grants receivable	(4,982)	3,465
Grants and other receivables	57,321	(344,602)
Contributions receivable	79,606	40,041
Prepaid expenses and other assets	(84,542)	64,057
Security deposits	500	-
Accounts payable	162,623	(228,432)
Accrued expenses	418,669	72,906
Accrued payroll and vacation	(190,483)	321,056
Grants payable	80,250	338,731
Deferred support and revenue	233,104	(78,344)
Operating lease payments	(680,659)	-
Net Cash from Operating Activities	(5,689,041)	4,575,774
 CASH FLOWS FROM INVESTING ACTIVITIES		
Purchases of investments	(296,842)	(21,375,164)
Proceeds from sale of investments	-	20,709,682
Net Cash from Investing Activities	(296,842)	(665,482)
 CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from Paycheck Protection Program	-	1,541,013
Net Change in Cash and Cash Equivalents	(5,985,883)	5,451,305
 CASH AND CASH EQUIVALENTS		
Beginning of year	18,424,427	12,973,122
End of year	\$ 12,438,544	\$ 18,424,427
 SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES		
Right-of-use asset obtained in exchange for lease obligation	\$ 67,561	\$ -
Paycheck Protection Program loan forgiveness	1,541,013	1,398,100
 SUPPLEMENTAL CASH FLOW INFORMATION		
Unrelated business income taxes paid	100,425	39,142

See notes to consolidated financial statements

The National Hemophilia Foundation and Affiliate

Notes to Consolidated Financial Statements
December 31, 2022 and 2021

1. Nature of Organization

The National Hemophilia Foundation (“NHF”) was incorporated in the State of New York on June 15, 1948. NHF’s mission is dedicated to finding cures for inheritable blood disorders and to addressing and preventing the complications of these disorders through research, education and advocacy, enabling people and families to thrive.

NHF and other independent organizations (“member chapters”) actively collaborate in furthering the Foundation’s mission throughout the United States. On June 23, 2011, five chapters merged with NHF. On February 24, 2014 and January 27, 2016 a sixth and seventh chapter was created by the Foundation; consequently, the two subsequently created chapters along with those of the five previously merged chapters are included in the consolidated financial statements of NHF. All other member chapters continue to operate independently of NHF and thus, are not included in the consolidated financial statements of NHF and are referred to as the “member chapters”.

Affiliate

NHF Venture Fund LLC/Pathway to Cures (“P2C”) was established during 2021 and operates as a nonprofit Delaware single member limited liability company. The National Hemophilia Foundation, its sole member, has limited liability for the obligations or debts of the entity. P2C is an initiative focused on fueling innovation and discovery in the treatment of inheritable blood disorders. P2C was formed to revolutionize treatments and health care for those living with inheritable blood disorders, and to create a model for broader transformation across the health care landscape. P2C is a venture philanthropy fund. Its core strategic focus is the development of novel and curative therapeutics and innovative technologies that have the potential to transform treatment modalities or disrupt the conventional care delivery model in a way that significantly closes health equity gaps for people with inheritable blood disorders.

P2C will invest donor funds in entrepreneurial biotech startups to accelerate research and development for the treatment of inheritable blood disorders. P2C will invest for societal impact and the potential for financial returns to the fund to fuel more investments and NHF’s mission of support for the inheritable blood disorders community and to help achieve NHF’s vision of a world without inheritable blood disorders.

Collectively, NHF and P2C are referred to as the Foundation.

The specific programs and services provided by the Foundation include the following:

Health Education and Training

The Foundation’s education division develops consumer and healthcare provider materials and conducts various educational events and programs including the annual Bleeding Disorders Conference, workshops, webinars and distributes information and resources through Hemophilia and AIDS/HIV Network for the Dissemination of Information (HANDI), NHF’s information resource center. Information and education is provided on all bleeding disorders for consumers, caretakers, healthcare providers and the general public.

The National Hemophilia Foundation and Affiliate

Notes to Consolidated Financial Statements
December 31, 2022 and 2021

1. Nature of Organization (*continued*)

Community Services

The Foundation's public policy department monitors emerging trends and identifies potential barriers to access health care both on a Federal and State level. It establishes and advocates for policies that promote the health, safety, rights and access to care for people with bleeding disorders by educating federal and state lawmakers, other government agencies and officials, industry and allied organizations. Two key areas of focus are self-advocacy for individuals with bleeding disorders and their families and caretakers and working with the Hemophilia Treatment Centers, chapters and payers to identify and remove barriers for accessing health care.

Research

The Foundation awards a wide range of grants to various educational and medical institutions for clinical fellowships, innovative research initiatives, Judith Graham Pool (JGP) postdoctoral research fellowships, clinical career development and health care provider grants. Research grants are funded for 1 - 3 years. The Foundation has created a consumer driven research platform, convened community members, synthesized and prioritized research questions to help drive the research agenda.

Chapter Services

The Foundation provides support and technical assistance to a network of its 53 member chapters that are located throughout the United States to serve affected members of the bleeding disorders community in their geographical areas. Additionally, Chapter Services offers education, resources, and board training to chapters. Chapter Services offers the chapters financial support in the form of capacity building grants and techniques and skills needed to enhance each chapter's growth and long-term sustainability.

2. Summary of Significant Accounting Policies

Basis of Presentation and Use of Estimates

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"), which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from these estimates.

Change in Accounting Policy

The Foundation adopted FASB Topic 842, *Leases*, using the effective date method with January 1, 2022, as the date of initial adoption, with certain practical expedients available.

The Foundation elected the available practical expedients to account for its existing operating lease under the new guidance, without reassessing (a) whether the contracts contain leases under the new standard, (b) whether classification of capital leases or operating leases would be different in accordance with the new guidance, or (c) whether the unamortized initial direct costs before transition adjustments would have met the definition of initial direct costs in the new guidance at lease commencement.

The National Hemophilia Foundation and Affiliate

Notes to Consolidated Financial Statements
December 31, 2022 and 2021

2. Summary of Significant Accounting Policies *(continued)*

Change in Accounting Policy (continued)

As a result of the adoption of the new lease accounting guidance, on January 1, 2022 the Foundation recognized a lease liability of \$2,482,816, that represents the present value of the remaining operating lease payments of \$2,557,971 discounted using the U.S. Treasury bond rate for 10 years of 1.63% and a right-of-use asset ("ROU asset") of \$2,281,067 that represents the operating lease liability of \$2,482,816, adjusted for prepaid rent of \$113,677 and deferred rent of \$315,426. Accordingly, there is no effect on net assets in connection with the implementation.

The standard had a material impact on the Foundation's consolidated statement of financial position but did not have an impact on its consolidated statements of activities and cash flows. The most significant impact was the recognition of a ROU asset and lease liability for an operating lease.

Principles of Consolidation

The consolidated financial statements include the accounts of NHF and P2C. P2C did not have significant activity during the years ended December 31, 2022 and 2021.

Cash and Cash Equivalents

Cash and cash equivalents include cash balances held in bank and investment accounts, money market accounts and highly liquid debt instruments with maturities of three months or less at the time of purchase.

Financial instruments that potentially subject the Foundation to concentrations of credit and market risk consist principally of cash and cash equivalents on deposit with financial institutions. Deposits held at financial institutions insured by the Federal Deposit Insurance Corporation ("FDIC") are insured up to \$250,000. At times cash balances may exceed the FDIC limit. As of December 31, 2022 and 2021, the Foundation's uninsured cash and cash equivalent balances on deposit totaled approximately \$10,719,000 and \$16,919,000.

Investment Valuation and Income Recognition

The Foundation records investment purchases at cost, or if donated, at fair value on the date of donation. Thereafter, investments are reported at their fair values in the consolidated statement of financial position. Return on investments is reported in the consolidated statement of activities and consists of interest and dividend income, realized and unrealized gains and losses, less external and direct internal investment expenses and is classified without donor restrictions unless its use is restricted by explicit donor stipulation or by law. Purchases and sales of investments are recorded on a settlement date basis. The cost of securities sold is determined using the specific identification method. The Foundation reviews its investments annually for impairment. Management has determined there are no other than temporary losses as of December 31, 2022 which are reflected in the consolidated statement of activities.

The National Hemophilia Foundation and Affiliate

Notes to Consolidated Financial Statements
December 31, 2022 and 2021

2. Summary of Significant Accounting Policies *(continued)*

Investment Valuation and Income Recognition (continued)

The Foundation maintains accounts at a financial investment institution. Investment holdings at financial institutions insured by the Securities Investor Protection Corporation ("SIPC") are insured up to \$500,000 (\$250,000 for cash holdings). At times balances may exceed the SIPC limit. As of December 31, 2022 and 2021, the Foundation's uninsured balance in investment holdings totaled approximately \$20,776,000 and \$25,042,000.

Cash equivalents and investments are exposed to various risks, such as interest rates, market and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the near-term could materially affect the amounts reported in the consolidated statement of financial position.

Receivables

Grants and contributions are recorded and discounted if due over more than one year using risk-free interest rates applicable in the year in which the promise was received.

Amortization of the discount is included in contributions and grants in the consolidated statement of activities. The discount will be recognized as contribution revenue in future years as the discount is amortized over the duration of the contribution period.

An allowance for uncollectible accounts is recorded by management, if necessary, for reimbursable expenses either in dispute with the funding agency or deemed uncollectible. Management has determined that no allowance is necessary as of December 31, 2022 and 2021.

At December 31, 2022 and 2021 approximately 33% and 48% of the Foundation's grants and other receivables is due from two and three grantors.

No other grantors accounted for more than 10% of grants and other receivables at December 31, 2022 and 2021.

Property and Equipment

Property and equipment are recorded at cost, or if received by donation, at their estimated fair value at the time such items are received. The Foundation's policy is to capitalize property and equipment acquisitions greater than \$5,000. Depreciation is provided using the straight-line method over the estimated useful life of the assets ranging from five to seven years. Leasehold improvements are amortized over the shorter of the life of the lease inclusive of expected renewals or their useful lives which is approximately 10 years.

When assets are disposed of, the related accumulated depreciation or amortization is also removed from the appropriate accounts and the resulting gain or loss is included in the consolidated statement of activities.

The National Hemophilia Foundation and Affiliate

Notes to Consolidated Financial Statements
December 31, 2022 and 2021

2. Summary of Significant Accounting Policies (*continued*)

Leases

As of January 1, 2022 the Foundation leases office space and determines if an arrangement is a lease at inception. Operating leases are included in ROU assets and operating lease liabilities on the accompanying consolidated statement of financial position.

ROU assets represent the right to use an underlying asset for the lease term and operating lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The leases do not provide an implicit borrowing rate. The Foundation elected to use the U.S. Treasury bond rate for a period comparable to the lease term in determining the present value of lease payments. The operating lease ROU asset includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Foundation will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

The Foundation's lease agreements do not contain any material residual value guarantees or material restrictive covenants.

The Foundation has lease agreements with lease and non-lease components, which are generally accounted for separately. For certain leases, such as office space the Foundation accounts for the lease and non-lease components as a single lease component. Variable lease components in these leases such as real estate taxes are recognized in operating expenses in the period in which the obligation is incurred.

The Foundation applies the short-term lease exemption to all its classes of underlying assets. During the year ended December 31, 2022, the short-term lease cost included in change in net assts is \$45,197.

Deferred Rent

For the year ended December 31, 2021, the Foundation had an operating lease inclusive of scheduled base rent increases over the term of the lease. The total amount of rent being charged each year was based on the straight-line method of payments for base rent due over the term of the lease. The Foundation has recorded a deferred rent liability to account for the difference between the actual payments and the straight-line expense, which began to reverse during the year ended December 31, 2020, when actual payments exceeded the straight-line expense. As a result of the implementation of FASB Topic 842, *Leases*, on January 1, 2022, deferred rent is now a component of the related operating lease liability.

The National Hemophilia Foundation and Affiliate

Notes to Consolidated Financial Statements
December 31, 2022 and 2021

2. Summary of Significant Accounting Policies *(continued)*

Net Asset Presentation

Net assets of the Foundation are classified based on the presence or absence of donor-imposed restrictions. Net assets are comprised of two groups as follows:

Net assets without donor restrictions: Amounts that are not subject to usage restrictions based on donor-imposed requirements. This class also includes assets previously restricted where restrictions have expired or been met. These net assets may be used at the discretion of the Foundation's management and Board of Directors (the "Board"). The Board has designated net assets for specified purposes. Board-designated net assets are comprised of the following at December 31,

	2022	2021
NHF Rebranding	\$ 320,000	\$ 550,000
CVR Registry	1,025,500	1,225,000
Pathway to Cures	2,296,500	3,000,000
Research - Bridge Grant	250,000	250,000
Chapter Capacity Building	-	40,000
Upcoming events	-	6,250
	<u>\$ 3,892,000</u>	<u>\$ 5,071,250</u>

Net assets with donor restrictions: Assets subject to usage limitations based on donor-imposed or grantor restrictions. Some donor-imposed restrictions are temporary in nature, such as those that will be met by the passage of time or other events specified by the donor. Other donor-imposed restrictions are perpetual in nature, where the donor stipulates that resources be maintained in perpetuity. Donor-imposed restrictions are released when a restriction expires, that is, when the stipulated time has elapsed, when the stipulated purpose for which the resource was restricted has been fulfilled, or both.

Earnings related to restricted net assets will be included in net assets without donor restrictions unless otherwise specifically required to be included in donor restricted net assets by the donor or by applicable state law.

Support and Revenue

Revenue is recognized when performance obligations are satisfied. Educational seminars and programs are recognized at the point in time when they are held. Educational and medical literature revenue is comprised of advertising revenues and is recognized at a point in time when print or electronic publications are issued.

Various economic factors affect revenues and cash flows. Revenue and cash flows related to educational seminars and programs and educational and medical literature are generally concurrent.

The National Hemophilia Foundation and Affiliate

Notes to Consolidated Financial Statements
December 31, 2022 and 2021

2. Summary of Significant Accounting Policies (*continued*)

Support and Revenue (continued)

Related accounts receivable as of December 31, 2022 and 2021 and January 1, 2021 totaled \$22,730, \$20,675 and \$59,865 and is included in grants and other receivables in the consolidated statement of financial position. Related deferred revenue as of December 31, 2022 and 2021 and January 1, 2021 totaled \$91,504, \$7,978 and \$17,322 and is included in deferred support and revenue in the consolidated statement of financial position.

Special Events Revenue

Donations made for special events are recognized in the year the donation is made, regardless of when the event takes place based upon the unconditional nature of the donations. In cases where there is a benefit received by the donor, the fair value of the value to be received by the donor is recognized as deferred revenue until the year the event occurs.

Contributions and Grants

The Foundation recognizes contributions and grants when cash, securities or other assets; an unconditional promise to give; or a notification of a beneficial interest is received. Conditional promises to give, that is, those with a measurable performance or other barrier and a right of return, are not recognized until the conditions on which they depend have been met. Grants and contributions are reported as net assets with donor restrictions if they are received with donor stipulations that limit the use of the donated assets.

For the years ended December 31, 2022 and 2021 approximately 50% and 18% of the Foundation's total support and revenue was provided by three and one pharmaceutical companies. Outstanding receivables due from these grantors at December 31, 2022 and 2021 accounted for 19% and 0% of grants and other receivables.

No other grantors accounted for more than 10% of revenue for the years ended December 31, 2022 and 2021.

Research Awards and Grants

The Foundation awards a wide range of grants to various educational and medical institutions for clinical fellowships, innovative research initiatives, bridge grants, clinical career development and health care provider grants. Research grants are funded for 1-3 years. Conditional promises to give, that is, those with a measurable performance or other barrier and a right of return, are not recognized until the conditions on which they depend have been met. The Foundation, therefore, only records the liability and related expenses for unconditional promises to give. Promises to give at December 31, 2022 and 2021 totaled \$1,545,750 and \$1,465,500 and are included in grants payable in the consolidated statement of financial position.

The National Hemophilia Foundation and Affiliate

Notes to Consolidated Financial Statements
December 31, 2022 and 2021

2. Summary of Significant Accounting Policies *(continued)*

Functional Allocation of Expenses

The costs of providing the various programs and support services have been summarized on a functional basis in the consolidated statement of activities. The consolidated statement of functional expenses presents expenses by function and natural classification. Expenses directly attributable to specific functional areas of the Foundation are reported as expenses of those functional areas while costs that benefit multiple functional areas have been allocated based on time and effort. Indirect costs have been allocated based on time and effort or all or part of the following expenditures: salaries, employee benefits and payroll taxes, pension expense, supplies, printing and other, telephone, occupancy, insurance, equipment rental and maintenance and depreciation and amortization.

Income Taxes

NHF is a not-for-profit corporation that is exempt from income tax, other than unrelated business income ("UBIT"), under Section 501 (c)(3) of the Internal Revenue Code of 1986, as amended ("Code"). In addition, NHF has been determined by the Internal Revenue Service ("IRS") not to be a private foundation within the meaning of section 509(a) of the Code.

NHF files IRS Form 990T for its activities which are subject to UBIT. For the years ended December 31, 2022 and 2021, UBIT totaled \$49,796 and \$94,869. These amounts have been included in the consolidated statement of functional expenses under printing and other, for the portion attributable to the production of the Hemaware magazine, both printed and online formats.

P2C is a single member LLC which is considered a disregarded entity.

Accounting for Uncertainty in Income Taxes

The Foundation recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Management has determined that the Foundation had no uncertain tax positions that would require financial statement recognition or disclosure. The Foundation is no longer subject to examinations by the applicable taxing jurisdictions for tax years prior to 2019.

Summarized Comparative Financial Information

The accompanying consolidated financial statements include prior-year summarized comparative information. Accordingly, such information should be read in conjunction with the Foundation's financial statements as of and for the year ended December 31, 2021, from which the summarized comparative financial information was derived.

Subsequent Events

Management has evaluated subsequent events for disclosure and/or recognition in the consolidated financial statements through the date that the consolidated financial statements were available to be issued, which date is June 16, 2023.

The National Hemophilia Foundation and Affiliate

Notes to Consolidated Financial Statements
December 31, 2022 and 2021

3. Availability and Liquidity

Management regularly monitors the availability of resources required to meet its operating needs. As part of management's liquidity plan, the Foundation has a policy to structure its financial assets to be available as its general expenses, liabilities, and other obligations come due. For purposes of analyzing resources available to meet general expenses over a twelve-month period, management considers all expenses related to its ongoing activities.

Financial assets available for general expenditure, that is, without donor or other restrictions limiting their use, within one year of the consolidated statement of financial position date, comprise the following at December 31,

	<u>2022</u>	<u>2021</u>
Financial assets at year-end without donor restrictions		
Cash and cash equivalents	\$ 5,913,349	\$ 8,012,670
Government grants receivable	47,925	42,943
Grants and other receivables	544,602	967,041
Investments	<u>18,132,750</u>	<u>22,935,609</u>
Total Financial Assets Without Donor Restrictions	24,638,626	31,958,263
Less amounts not available to be used within one year:		
Board designated funds	<u>(3,892,000)</u>	<u>(5,071,250)</u>
Financial Assets Available to Meet General Expenditures Over the Next Twelve Months	<u>\$ 20,746,626</u>	<u>\$ 26,887,013</u>

In addition to financial assets available to meet general expenditures over the next twelve months, the Foundation anticipates collecting sufficient revenue to cover general expenses.

4. Fair Value Measurements

Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 820, Fair Value Measurements FASB ASC 820, establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement.) The carrying amounts of cash and cash equivalents included in the accompanying consolidated statement of financial position approximated fair value at December 31, 2022 and 2021 are not presented in the following table. The three levels of the fair value hierarchy under FASB ASC 820 are described as follows:

Level 1 - Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets.

Level 2 - Inputs to the valuation methodology include:

- quoted prices for similar assets or liabilities in active markets;
- quoted prices for identical or similar assets or liabilities in inactive markets;
- inputs other than quoted prices that are observable for the asset or liability;
- inputs that are derived principally from or corroborated by observable market data by correlation or other means.

The National Hemophilia Foundation and Affiliate

Notes to Consolidated Financial Statements
December 31, 2022 and 2021

4. Fair Value Measurements (*continued*)

Level 3 – Inputs to the valuation methodology are unobservable and significant to the fair valuemmeasurement.

The asset and liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

Following is a description of the valuation methodologies used for assets and liabilities measured at fair value.

- *Stocks and Mutual Funds*: Valued at the closing price reported on the New York Stock Exchange

The preceding methods may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Foundation believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

The following table sets forth the Foundation's investments, measured at fair value using quoted prices (Level 1) as of December 31,

	<u>2022</u>	<u>2021</u>
Mutual Funds - Fixed Income	\$ 8,888,627	\$10,232,787
Mutual Funds - Equity		
U.S.	7,485,730	9,297,541
International	<u>4,901,898</u>	<u>6,012,134</u>
	21,276,255	25,542,462
Investments for Deferred Compensation		
Mutual Funds - U.S.	351,775	594,746
	<u>\$21,628,030</u>	<u>\$26,137,208</u>

The National Hemophilia Foundation and Affiliate

Notes to Consolidated Financial Statements
December 31, 2022 and 2021

4. Fair Value Measurements (continued)

Return on investments consists of the following for the years ended December 31,

	<u>2022</u>	<u>2021</u>
Interest and dividend income	\$ 402,236	\$ 770,403
Net realized (loss) gain	(1,419)	2,120,737
Net unrealized loss	<u>(4,561,630)</u>	<u>(341,966)</u>
Return on Investments	(4,160,813)	2,549,174
Investment management fees	<u>(45,242)</u>	<u>(42,056)</u>
Total Return on Investments	<u>\$ (4,206,055)</u>	<u>\$ 2,507,118</u>

5. Contributions Receivable

Unconditional promises to give from donors were restricted as of December 31, 2022 and 2021. Unconditional promises to give consists of the following at December 31,

	<u>2022</u>	<u>2021</u>
Less than one year	\$ 60,000	\$ 80,188
One to five years	<u>-</u>	<u>60,000</u>
	60,000	140,188
Less: Discount to present value	<u>-</u>	<u>582</u>
	<u>\$ 60,000</u>	<u>\$ 139,606</u>

6. Property and Equipment

Property and equipment consists of the following at December 31,

	<u>2022</u>	<u>2021</u>
Furniture, fixtures and equipment	\$ 315,305	\$ 315,305
Computers	157,433	157,433
Leasehold improvements	<u>51,576</u>	<u>51,576</u>
	524,314	524,314
Less: Accumulated depreciation and amortization	<u>432,741</u>	<u>384,302</u>
	<u>\$ 91,573</u>	<u>\$ 140,012</u>

Depreciation and amortization expense totaled \$48,439 and \$76,663 for the years ended December 31, 2022 and 2021.

The National Hemophilia Foundation and Affiliate

Notes to Consolidated Financial Statements
December 31, 2022 and 2021

7. Leases

The Foundation has operating leases for office space in New York and Nebraska.

The components of lease costs are included in occupancy in the consolidated statement of functional expenses and were as follows for the year ended December 31, 2022:

Rent expense	
Operating lease costs	\$ 646,324
Short-term lease costs	<u>45,197</u>
	<u>\$ 691,521</u>

Information associated with the measurement of the Foundation's operating lease obligations as of December 31, 2022 is as follows:

Weighted-average remaining lease term in years for operating leases	2.74
Weighted-average discount rate for operating leases	1.71%

These leases have remaining lease terms of 3 to 5 years, and one includes an option to extend for two additional one-year terms. As of December 31, 2022, maturities for operating lease liabilities were as follows for the years ending:

2023	\$ 706,693
2024	722,342
2025	495,585
2026	15,358
2027	<u>11,690</u>
Total Future Minimum Lease Payments	1,951,668
Less imputed Interest	<u>(45,899)</u>
Total Operating Lease Liabilities	<u>\$ 1,905,769</u>

Cash paid for leases during the year ended December 31, 2022 totaled \$458,308.

Subsequent to the year ended December 31, 2022, the Foundation terminated their New York operating lease in consideration of \$947,142. In March 2023, the Foundation entered into a non-cancellable lease agreement for one-year and twelve-days. The lease requires current monthly payments of \$4,140, net of a \$460 membership credit per month. Upon the expiration of the lease, the agreement will remain in full force on a month-to-month basis, until written notice by the Foundation, no earlier than the expiration date, or by sole discretion of the lessor.

The National Hemophilia Foundation and Affiliate

Notes to Consolidated Financial Statements
December 31, 2022 and 2021

7. Leases (continued)

For the year ended December 31, 2021, rent expense, including real estate taxes, totaled \$716,345 and is included in occupancy in the consolidated statement of functional expenses.

8. Paycheck Protection Program Loan

On April 24, 2020, the Foundation received loan proceeds in the amount of \$1,398,100 under the Paycheck Protection Program (the "PPP"). The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (the "CARES Act"), provides for loans to qualifying entities for amounts up to 2.5 times their 2019 average monthly payroll expenses of the qualifying entity. On March 30, 2021, the Foundation received loan proceeds in the amount of \$1,541,013 under Second Draw provisions of the PPP as authorized by the Economic Aid to Hard-Hit Small Businesses, Nonprofits, and Venues Act (the "Economic Aid Act"). The Second Draw provisions of the Economic Aid Act provides for loans to qualifying entities for amounts up to 2.5 or 3.5 times their 2019 or 2020 average monthly payroll expenses. The PPP loans bear an interest rate of 1% per annum.

All or a portion of the PPP loans' principal and accrued interest are forgivable as long as the borrower uses the loan proceeds for eligible purposes, as described in the CARES Act as amended by the Economic Aid Act, over a period between eight to twenty-four weeks from the date the loan proceeds are received (the "Covered Period"). The amount of loan forgiveness could be reduced if the borrower terminates employees or reduces salaries below a certain threshold during the Covered Period and does not qualify for certain safe harbors. On April 16, 2021, the SBA has notified the Foundation that the First Draw PPP loan has been fully forgiven and is included in Paycheck Protection Program loan forgiveness in the 2021 consolidated statement of activities.

As of December 31, 2021, the Second Draw PPP loan is recognized as debt in the consolidated statement of financial position. The Foundation recognized the income from the forgiveness of the Second Draw PPP loan, in accordance with Accounting Standards Codification ("ASC") 470, *Debt*, upon receiving the notification of forgiveness from the SBA in June 2022 and is included in Paycheck Protection Program loan forgiveness in the 2022 consolidated statement of activities.

9. Grants Payable

The Foundation has agreements with various institutions that are payable in installments. These unconditional grant agreements require the institutions to continue appropriate performance and provide certain financial and non-financial reports to the Foundation. Outstanding grant commitments payable are as follows as of December 31,

	<u>2022</u>	<u>2021</u>
Less than one year	\$ 1,211,750	\$ 865,500
One to five years	<u>334,000</u>	<u>600,000</u>
	<u>\$ 1,545,750</u>	<u>\$ 1,465,500</u>

At December 31, 2022 and 2021, management determined a present value discount would be insignificant and elected not to recognize a discount.

The National Hemophilia Foundation and Affiliate

Notes to Consolidated Financial Statements
December 31, 2022 and 2021

10. Retirement Benefit Plans

The Foundation has a defined contribution plan organized under Section 403(b) of the Internal Revenue Code administered by TIAA-CREF Individual and Institutional Services, Inc. covering substantially all of its employees. The Foundation makes contributions for each participant in the amount of a stated percentage of annual compensation based on the number of years such participant is in the employ of the Foundation. Employees also may contribute to another 403(b) plan subject to the maximum annual contribution limit prescribed by the Employee Retirement Income Security Act of 1974 guidelines. The Foundation also provides a nonqualified deferred compensation plan for certain executives that operate under Section 457(b) of the Internal Revenue Code. For the years ended December 31, 2022 and 2021, expenses for benefit plans totaled \$615,702 and \$554,241 and are included in pension expense in the consolidated statement of functional expenses.

11. Net Assets With Donor Restrictions

Net assets with donor restrictions represent contributions and grants received, and income related to the following at December 31,

	<u>2022</u>	<u>2021</u>
Purpose or Time Restrictions		
Endowments		
Research - unappropriated endowment earnings	\$ 285,311	\$ 646,385
Dale Smith Endowment Fund	250,000	250,000
Hemophilia of Georgia Endowment Fund	<u>1,250,000</u>	<u>1,250,000</u>
	<u>1,500,000</u>	<u>1,500,000</u>
Total Endowments	<u>1,785,311</u>	<u>2,146,385</u>
Research	4,315,330	4,507,927
Health education and training	1,702,110	2,718,128
Chapter services	662,069	1,183,578
Community services	<u>1,674,083</u>	<u>2,765,342</u>
	<u>8,353,592</u>	<u>11,174,975</u>
 Total Net Assets With Donor Restrictions	 <u>\$ 10,138,903</u>	 <u>\$ 13,321,360</u>

Research endowments are subject to appropriation and expenditure when a specified event occurs. The Dale Smith Endowment Fund and Hemophilia of Georgia Endowment Fund are perpetual in nature and earnings from each of the endowment funds are subject to the endowment spending policy and appropriation.

The National Hemophilia Foundation and Affiliate

Notes to Consolidated Financial Statements
December 31, 2022 and 2021

12. Net Assets Released from Restrictions

Net assets with donor restrictions were released from net assets with donor restrictions by incurring expenses satisfying the following restricted purposes or by the passage of time:

	<u>2022</u>	<u>2021</u>
Satisfaction of Purpose Restrictions		
Research	\$ 1,224,282	\$ 817,345
Health education and training	888,333	1,231,203
Chapter services	541,679	125,914
Community services	926,127	1,120,485
	<u>\$ 3,580,421</u>	<u>\$ 3,294,947</u>

13. Endowment Funds

The Foundation maintains donor-restricted funds whose purpose is to provide long-term support for its qualifying fellowships and research programs. As required by U.S. GAAP, net assets associated with endowment funds are classified and reported based on the existence or absence of donor-imposed restrictions.

Interpretation of Relevant Law

The Board has interpreted the New York Prudent Management of Institutional Funds Act ("NYPMIFA") as requiring the preservation of the fair value of the original gift as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary.

As a result of this interpretation, the Foundation classifies as perpetual net assets with donor restrictions (a) the original value of gifts donated to the perpetual endowment, (b) original gift of subsequent gifts to the perpetual endowment, and (c) accumulations to the perpetual endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund. The remaining portion of the donor-restricted endowment fund that is not retained in perpetuity is classified as purpose restricted net assets until those amounts are appropriated for expenditure by the Board in a manner consistent with the standard of prudence prescribed by NYPMIFA.

Investment Objectives

The Foundation has adopted an investment policy that primarily emphasizes the preservation of the capital and secondarily maximizes the total return. Investment returns are expected to provide adequate funds to sufficiently support designated needs and preserve or enhance the real value of the Foundation. Additionally, the Foundation requires the strategic asset allocation to be reviewed annually to maximize the diversity of the investments and to minimize risk. In establishing the investment objectives of the Foundation, the finance committee of the Board has taken into account the time horizon available for investment, the nature of the Foundation's cash flows and liabilities, and other factors that impact the Foundation's risk tolerance.

The National Hemophilia Foundation and Affiliate

Notes to Consolidated Financial Statements
December 31, 2022 and 2021

13. Endowment Funds (continued)

Strategies Employed for Achieving Objectives

To satisfy its long-term objectives, the Foundation will ensure appropriate diversification to marketable equity securities. There shall be no Securities and Exchange Commission unregistered securities, private placement, venture capital, or direct investments in real or personal property. Approved investments include among others equity securities and fixed income securities.

Spending Policy

The Foundation determines the appropriation on an annual basis for expenditure at the rate up to 4% of the fund's average fair value over the most recent thirty-six-month period taking into consideration relevant economic, investment, and financial conditions. Net amounts available for release accumulated from previous years total \$285,311 and \$646,385 as of December 31, 2022 and 2021, and are recorded as net assets with donor restrictions until released for research awards.

From time to time, certain donor-restricted endowment funds may have fair values less than the amount required to be maintained by donors or by law (underwater endowments). The Foundation has interpreted UPMIFA to permit spending from underwater endowments in accordance with prudent measures required under law. At December 31, 2022 and 2021, there were no underwater endowments.

Changes in Donor-Restricted Endowment Net Assets

	2022	2021
Balance - beginning of year	\$ 2,146,385	\$ 1,983,771
Investment return	(361,074)	211,918
Spend rate appropriation	-	(49,304)
Balance - end of year	<u>\$ 1,785,311</u>	<u>\$ 2,146,385</u>

14. Litigation

The Foundation is a defendant in a legal proceeding arising during the normal course of business. During 2022, management accrued \$500,000 which is based on its best estimate based on information currently available and is included in accrued expenses in the consolidated statement of financial position. It is reasonably possible that a change in estimate can occur in the near term.

* * * * *

The National Hemophilia Foundation and Affiliate

Supplementary Information
December 31, 2022

The National Hemophilia Foundation and Affiliate
Central Ohio Chapter

Statement of Financial Position
December 31, 2022
(With summarized totals at December 31, 2021)

	2022			2021
	Without Donor Restrictions	With Donor Restrictions	Total	Total
ASSETS				
Cash and cash equivalents	\$ 367,571	\$ 2,937	\$ 370,508	\$ 391,475
Grants and other receivables	53,300	-	53,300	39,950
Intercompany receivable	47,454	-	47,454	62,205
	<u>\$ 468,325</u>	<u>\$ 2,937</u>	<u>\$ 471,262</u>	<u>\$ 493,630</u>
LIABILITY AND NET ASSETS				
Liability				
Accounts payable	\$ 27,302	\$ -	\$ 27,302	\$ 241
Net Assets				
Without donor restrictions - undesignated	441,023	-	441,023	444,751
With donor restrictions - restricted by purpose or time	-	2,937	2,937	48,638
Total Net Assets	<u>441,023</u>	<u>2,937</u>	<u>443,960</u>	<u>493,389</u>
	<u>\$ 468,325</u>	<u>\$ 2,937</u>	<u>\$ 471,262</u>	<u>\$ 493,630</u>

See Independent Auditors' Report

**The National Hemophilia Foundation and Affiliate
Central Ohio Chapter**

Statement of Activities
Year Ended December 31, 2022
(With summarized totals for the year ended December 31, 2021)

	2022			2021
	Without Donor Restrictions	With Donor Restrictions	Total	Total
SUPPORT AND REVENUE				
Special events revenue	\$ 10,230	\$ -	\$ 10,230	\$ 30,167
Contributions and grants	68,890	-	68,890	199,511
Revenues generated from NHF and chapters	-	-	-	16,900
Educational/medical literature	6,900	-	6,900	42,850
Net assets released from restrictions	<u>45,701</u>	<u>(45,701)</u>	<u>-</u>	<u>-</u>
Total Support and Revenue	<u>131,721</u>	<u>(45,701)</u>	<u>86,020</u>	<u>289,428</u>
EXPENSES				
Program Services				
Health education and training	21,164	-	21,164	27,647
Community services	<u>76,497</u>	<u>-</u>	<u>76,497</u>	<u>73,156</u>
Total Program Services	<u>97,661</u>	<u>-</u>	<u>97,661</u>	<u>100,803</u>
Supporting Services				
Management and general	24,835	-	24,835	16,447
Fundraising	<u>12,953</u>	<u>-</u>	<u>12,953</u>	<u>8,400</u>
Total Supporting Services	<u>37,788</u>	<u>-</u>	<u>37,788</u>	<u>24,847</u>
Total Expenses	<u>135,449</u>	<u>-</u>	<u>135,449</u>	<u>125,650</u>
Change in Net Assets	(3,728)	(45,701)	(49,429)	163,778
NET ASSETS				
Beginning of year	<u>444,751</u>	<u>48,638</u>	<u>493,389</u>	<u>329,611</u>
End of year	<u>\$ 441,023</u>	<u>\$ 2,937</u>	<u>\$ 443,960</u>	<u>\$ 493,389</u>

See Independent Auditors' Report

**The National Hemophila Foundation and Affiliate
Central Ohio Chapter**

**Statement of Functional Expenses
Year Ended December 31, 2022
(With summarized totals for the year ended December 31, 2021)**

	2022						2021	
	Program Services			Supporting Services			Total Expenses	Total
	Health Education and Training	Community Services	Total Program Services	Management and General	Fundraising	Total Supporting Services		
Salaries	\$ 7,898	\$ 17,376	\$ 25,274	\$ 6,319	\$ -	\$ 6,319	\$ 31,593	\$ 38,493
Employee benefits and payroll taxes	2,491	5,480	7,971	1,993	-	1,993	9,964	3,719
Pension expense	775	1,705	2,480	620	-	620	3,100	1,756
Total Salaries and Related Expenses	11,164	24,561	35,725	8,932	-	8,932	44,657	43,968
Supplies	-	-	-	51	-	51	51	5,152
Printing	-	2,238	2,238	-	-	-	2,238	4,880
Telephone	-	-	-	1,221	-	1,221	1,221	1,174
Occupancy	-	-	-	1,740	-	1,740	1,740	-
Insurance	-	-	-	136	-	136	136	-
Equipment rental and maintenance	-	1,980	1,980	-	450	450	2,430	1,980
Travel, conferences and conventions	-	1,300	1,300	19	-	19	1,319	13,838
Accounting and auditing	-	-	-	600	-	600	600	800
Consulting and professional fees	-	1,790	1,790	-	-	-	1,790	3,770
Membership dues	-	660	660	1,641	-	1,641	2,301	1,878
Awards and grants	10,000	43,935	53,935	10,000	12,500	22,500	76,435	46,206
Postage and shipping	-	33	33	96	-	96	129	1,319
Banking fees	-	-	-	399	3	402	402	685
Total Expenses	\$ 21,164	\$ 76,497	\$ 97,661	\$ 24,835	\$ 12,953	\$ 37,788	\$ 135,449	\$ 125,650

See Independent Auditors' Report

**The National Hemophilia Foundation and Affiliate
Idaho Chapter**

Statement of Financial Position
December 31, 2022
(With summarized totals at December 31, 2021)

	2022			2021
	Without Donor Restrictions	With Donor Restrictions	Total	Total
ASSETS				
Cash and cash equivalents	\$ 263,658	\$ 3,000	\$ 266,658	\$ 290,575
Grants and other receivables	17,000	-	17,000	1,750
Prepaid expenses and other assets	1,633	-	1,633	-
Security deposits	-	-	-	500
	<u>\$ 282,291</u>	<u>\$ 3,000</u>	<u>\$ 285,291</u>	<u>\$ 292,825</u>
LIABILITIES AND NET ASSETS				
Liabilities				
Accrued expenses	\$ 4,406	\$ -	\$ 4,406	\$ -
Deferred support and revenue	19,748	-	19,748	-
Intercompany payable	66,823	-	66,823	54,926
Total Liabilities	<u>90,977</u>	<u>-</u>	<u>90,977</u>	<u>54,926</u>
Net Assets				
Without donor restrictions - undesignated	191,314	-	191,314	212,771
With donor restrictions - restricted by purpose or time	-	3,000	3,000	25,128
Total Net Assets	<u>191,314</u>	<u>3,000</u>	<u>194,314</u>	<u>237,899</u>
	<u>\$ 282,291</u>	<u>\$ 3,000</u>	<u>\$ 285,291</u>	<u>\$ 292,825</u>

See Independent Auditors' Report

**The National Hemophilia Foundation and Affiliate
Idaho Chapter**

Statement of Activities
Year Ended December 31, 2022
(With summarized totals for the year ended December 31, 2021)

	2022			2021
	Without Donor Restrictions	With Donor Restrictions	Total	Total
SUPPORT AND REVENUE				
Special events revenue	\$ 21,554	\$ -	\$ 21,554	\$ 17,647
Contributions and grants	124,911	-	124,911	145,416
Revenues generated from NHF and chapters	-	-	-	22,750
Contributions from Combined Federal Campaign	301	-	301	-
Educational/medical literature	5,900	-	5,900	23,450
Net assets released from restrictions	22,128	(22,128)	-	-
Total Support and Revenue	<u>174,794</u>	<u>(22,128)</u>	<u>152,666</u>	<u>209,263</u>
EXPENSES				
Program Services				
Health education and training	86,304	-	86,304	56,269
Community services	65,638	-	65,638	50,483
Total Program Services	<u>151,942</u>	<u>-</u>	<u>151,942</u>	<u>106,752</u>
Supporting Services				
Management and general	24,822	-	24,822	35,629
Fundraising	19,487	-	19,487	7,686
Total Supporting Services	<u>44,309</u>	<u>-</u>	<u>44,309</u>	<u>43,315</u>
Total Expenses	<u>196,251</u>	<u>-</u>	<u>196,251</u>	<u>150,067</u>
Change in Net Assets	(21,457)	(22,128)	(43,585)	59,196
NET ASSETS				
Beginning of year	<u>212,771</u>	<u>25,128</u>	<u>237,899</u>	<u>178,703</u>
End of year	<u>\$ 191,314</u>	<u>\$ 3,000</u>	<u>\$ 194,314</u>	<u>\$ 237,899</u>

See Independent Auditors' Report

**The National Hemophilia Foundation and Affiliate
Idaho Chapter**

Statement of Functional Expenses
Year Ended December 31, 2022
(With summarized totals for the year ended December 31, 2021)

	2022						2021	
	Program Services			Supporting Services			Total	Total
	Health Education and Training	Community Services	Total Program Services	Management and General	Fundraising	Total Supporting Services		
Salaries	\$ 32,186	\$ 36,080	\$ 68,266	\$ 7,857	\$ 11,882	\$ 19,739	\$ 88,005	\$ 68,033
Employee benefits and payroll taxes	2,809	3,118	5,927	677	1,040	1,717	7,644	5,941
Pension expense	2,269	2,937	5,206	667	801	1,468	6,674	3,915
Total Salaries and Related Expenses	<u>37,264</u>	<u>42,135</u>	<u>79,399</u>	<u>9,201</u>	<u>13,723</u>	<u>22,924</u>	<u>102,323</u>	<u>77,889</u>
Supplies	1,570	2,334	3,904	935	2,597	3,532	7,436	11,064
Printing	40	8,085	8,125	634	-	634	8,759	6,017
Telephone	-	-	-	2,003	-	2,003	2,003	3,363
Occupancy	-	-	-	3,525	-	3,525	3,525	7,750
Insurance	-	-	-	1,306	-	1,306	1,306	294
Equipment rental and maintenance	-	-	-	2,618	-	2,618	2,618	1,550
Travel, conferences and conventions	46,666	9,844	56,510	2,253	3,075	5,328	61,838	30,719
Accounting and auditing	-	-	-	400	-	400	400	500
Consulting and professional fees	368	150	518	500	-	500	1,018	280
Membership dues	-	-	-	381	-	381	381	1,120
Awards and grants	300	3,008	3,308	-	-	-	3,308	5,650
Postage and shipping	96	79	175	55	22	77	252	2,564
Banking fees	-	3	3	1,011	70	1,081	1,084	1,307
Total Expenses	<u>\$ 86,304</u>	<u>\$ 65,638</u>	<u>\$ 151,942</u>	<u>\$ 24,822</u>	<u>\$ 19,487</u>	<u>\$ 44,309</u>	<u>\$ 196,251</u>	<u>\$ 150,067</u>

See Independent Auditors' Report

**The National Hemophilia Foundation and Affiliate
Nevada Chapter**

Statement of Financial Position
December 31, 2022
(With summarized totals at December 31, 2021)

	2022			2021
	Without Donor Restrictions	With Donor Restrictions	Total	Total
ASSETS				
Cash and cash equivalents	\$ 506,216	\$ 32,282	\$ 538,498	\$ 676,518
Grants and other receivables	100,021	-	100,021	41,250
Prepaid expenses and other assets	10,118	-	10,118	21,208
Security deposits	1,800	-	1,800	1,800
	<u>\$ 618,155</u>	<u>\$ 32,282</u>	<u>\$ 650,437</u>	<u>\$ 740,776</u>
LIABILITIES AND NET ASSETS				
Liabilities				
Accounts payable	\$ 2,500	\$ -	\$ 2,500	\$ -
Deferred support and revenue	13,000	-	13,000	200
Intercompany payable	119,551	-	119,551	60,997
Total Liabilities	<u>135,051</u>	<u>-</u>	<u>135,051</u>	<u>61,197</u>
Net Assets				
Without donor restrictions - undesignated	483,104	-	483,104	642,814
With donor restrictions - restricted by purpose or time	<u>-</u>	<u>32,282</u>	<u>32,282</u>	<u>36,765</u>
Total Net Assets	<u>483,104</u>	<u>32,282</u>	<u>515,386</u>	<u>679,579</u>
	<u>\$ 618,155</u>	<u>\$ 32,282</u>	<u>\$ 650,437</u>	<u>\$ 740,776</u>

See Independent Auditors' Report

**The National Hemophilia Foundation and Affiliate
Nevada Chapter**

Statement of Activities
Year Ended December 31, 2022
(With summarized totals for the year ended December 31, 2021)

	2022		2021	
	Without Donor Restrictions	With Donor Restrictions	Total	Total
SUPPORT AND REVENUE				
Special events revenue	\$ 49,036	\$ -	\$ 49,036	\$ 88,979
Contributions and grants	236,574	-	236,574	326,203
Revenues generated from NHF and chapters	16,000	-	16,000	48,850
Educational/medical literature	13,550	-	13,550	14,400
Other income	54	-	54	20
Net assets released from restrictions	4,483	(4,483)	-	-
Total Support and Revenue	<u>319,697</u>	<u>(4,483)</u>	<u>315,214</u>	<u>478,452</u>
EXPENSES				
Program Services				
Health education and training	132,500	-	132,500	79,869
Community services	194,901	-	194,901	197,132
Total Program Services	<u>327,401</u>	<u>-</u>	<u>327,401</u>	<u>277,001</u>
Supporting Services				
Management and general	73,692	-	73,692	66,356
Fundraising	78,314	-	78,314	75,072
Total Supporting Services	<u>152,006</u>	<u>-</u>	<u>152,006</u>	<u>141,428</u>
Total Expenses	<u>479,407</u>	<u>-</u>	<u>479,407</u>	<u>418,429</u>
Change in Net Assets	(159,710)	(4,483)	(164,193)	60,023
NET ASSETS				
Beginning of year	<u>642,814</u>	<u>36,765</u>	<u>679,579</u>	<u>619,556</u>
End of year	<u>\$ 483,104</u>	<u>\$ 32,282</u>	<u>\$ 515,386</u>	<u>\$ 679,579</u>

See Independent Auditors' Report

**The National Hemophilia Foundation and Affiliate
Nevada Chapter**

**Statement of Functional Expenses
Year Ended December 31, 2022
(With summarized totals for the year ended December 31, 2021)**

	2022						2021	
	Program Services			Supporting Services			Total	Total
	Health Education and Training	Community Services	Total Program Services	Management and General	Fundraising	Total Supporting Services		
Salaries	\$ 68,312	\$ 103,413	\$ 171,725	\$ 10,957	\$ 58,718	\$ 69,675	\$ 241,400	\$ 152,606
Employee benefits and payroll taxes	15,585	23,668	39,253	2,386	8,619	11,005	50,258	69,684
Pension expense	369	515	884	39	105	144	1,028	5,323
Total Salaries and Related Expenses	<u>84,266</u>	<u>127,596</u>	<u>211,862</u>	<u>13,382</u>	<u>67,442</u>	<u>80,824</u>	<u>292,686</u>	<u>227,613</u>
Supplies	5,615	3,379	8,994	1,197	1,981	3,178	12,172	36,179
Printing	114	10,055	10,169	-	-	-	10,169	6,469
Telephone	-	-	-	5,999	-	5,999	5,999	7,578
Occupancy	-	-	-	19,165	-	19,165	19,165	17,840
Equipment rental and maintenance	-	1,910	1,910	14,924	-	14,924	16,834	6,736
Travel, conferences and conventions	39,343	13,972	53,315	4,486	4,889	9,375	62,690	36,020
Accounting and auditing	-	-	-	1,000	-	1,000	1,000	1,200
Consulting and professional fees	2,808	4,216	7,024	9,879	2,090	11,969	18,993	30,225
Membership dues	-	1,005	1,005	1,541	-	1,541	2,546	7,149
Awards and grants	160	30,538	30,698	1,629	-	1,629	32,327	30,759
Postage and shipping	194	2,230	2,424	319	136	455	2,879	5,550
Banking fees	-	-	-	171	1,776	1,947	1,947	5,111
Total Expenses	<u>\$ 132,500</u>	<u>\$ 194,901</u>	<u>\$ 327,401</u>	<u>\$ 73,692</u>	<u>\$ 78,314</u>	<u>\$ 152,006</u>	<u>\$ 479,407</u>	<u>\$ 418,429</u>

See Independent Auditors' Report

**The National Hemophilia Foundation and Affiliate
Colorado Chapter**

Statement of Financial Position
December 31, 2022
(With summarized totals at December 31, 2021)

	2022			2021
	Without Donor Restrictions	With Donor Restrictions	Total	Total
ASSETS				
Cash and cash equivalents	\$ 672,772	\$ 10,000	\$ 682,772	\$ 781,828
Grants and other receivables	183,215	-	183,215	80,366
Prepaid expenses and other assets	2,880	-	2,880	1,625
	<u>\$ 858,867</u>	<u>\$ 10,000</u>	<u>\$ 868,867</u>	<u>\$ 863,819</u>
LIABILITIES AND NET ASSETS				
Liabilities				
Accounts payable	\$ -	\$ -	\$ -	\$ 4,500
Intercompany payable	86,029	-	86,029	132,484
Total Liabilities	<u>86,029</u>	<u>-</u>	<u>86,029</u>	<u>136,984</u>
Net Assets				
Without donor restrictions - undesignated	772,838	-	772,838	710,353
With donor restrictions - restricted by purpose or time	<u>-</u>	<u>10,000</u>	<u>10,000</u>	<u>16,482</u>
Total Net Assets	<u>772,838</u>	<u>10,000</u>	<u>782,838</u>	<u>726,835</u>
	<u>\$ 858,867</u>	<u>\$ 10,000</u>	<u>\$ 868,867</u>	<u>\$ 863,819</u>

See Independent Auditors' Report

**The National Hemophilia Foundation and Affiliate
Colorado Chapter**

Statement of Activities
Year Ended December 31, 2022
(With summarized totals for the year ended December 31, 2021)

	2022			2021
	Without Donor Restrictions	With Donor Restrictions	Total	Total
SUPPORT AND REVENUE				
Special events revenue	\$ 52,858	\$ -	\$ 52,858	\$ 68,886
Contributions and grants	406,868	10,000	416,868	369,328
Revenues generated from NHF and chapters	27,500	-	27,500	35,900
Educational/medical literature	27,332	-	27,332	20,332
Net assets released from restrictions	<u>16,482</u>	<u>(16,482)</u>	<u>-</u>	<u>-</u>
Total Support and Revenue	<u>531,040</u>	<u>(6,482)</u>	<u>524,558</u>	<u>494,446</u>
EXPENSES				
Program Services				
Health education and training	131,793	-	131,793	116,667
Community services	<u>229,320</u>	<u>-</u>	<u>229,320</u>	<u>202,985</u>
Total Program Services	<u>361,113</u>	<u>-</u>	<u>361,113</u>	<u>319,652</u>
Supporting Services				
Management and general	86,686	-	86,686	80,559
Fundraising	<u>20,756</u>	<u>-</u>	<u>20,756</u>	<u>23,254</u>
Total Supporting Services	<u>107,442</u>	<u>-</u>	<u>107,442</u>	<u>103,813</u>
Total Expenses	<u>468,555</u>	<u>-</u>	<u>468,555</u>	<u>423,465</u>
Change in Net Assets	62,485	(6,482)	56,003	70,981
NET ASSETS				
Beginning of year	<u>710,353</u>	<u>16,482</u>	<u>726,835</u>	<u>655,854</u>
End of year	<u>\$ 772,838</u>	<u>\$ 10,000</u>	<u>\$ 782,838</u>	<u>\$ 726,835</u>

See Independent Auditors' Report

**The National Hemophilia Foundation and Affiliate
Colorado Chapter**

**Statement of Functional Expenses
Year Ended December 31, 2022
(With summarized totals for the year ended December 31, 2021)**

	2022						2021	
	Program Services			Supporting Services			Total	Total
	Health Education and Training	Community Services	Total Program Services	Management and General	Fundraising	Total Supporting Services		
Salaries	\$ 59,348	\$ 68,812	\$ 128,160	\$ 34,117	\$ 8,144	\$ 42,261	\$ 170,421	\$ 177,699
Employee benefits and payroll taxes	15,262	18,329	33,591	7,574	2,113	9,687	43,278	42,414
Pension expense	2,723	3,179	5,902	1,532	403	1,935	7,837	4,345
Total Salaries and Related Expenses	<u>77,333</u>	<u>90,320</u>	<u>167,653</u>	<u>43,223</u>	<u>10,660</u>	<u>53,883</u>	<u>221,536</u>	<u>224,458</u>
Supplies	3,758	5,978	9,736	374	393	767	10,503	37,433
Printing	790	-	790	468	-	468	1,258	2,839
Telephone	-	-	-	4,347	-	4,347	4,347	3,542
Occupancy	-	-	-	21,847	-	21,847	21,847	21,318
Insurance	-	1,306	1,306	-	-	-	1,306	2,464
Equipment rental and maintenance	-	1,419	1,419	4,848	-	4,848	6,267	2,230
Travel, conferences and conventions	49,584	80,044	129,628	2,633	4,297	6,930	136,558	46,241
Accounting and auditing	-	-	-	1,000	-	1,000	1,000	1,100
Consulting and professional fees	-	25,205	25,205	-	5,405	5,405	30,610	35,165
Membership dues	-	850	850	4,062	-	4,062	4,912	11,454
Awards and grants	-	24,013	24,013	2,125	-	2,125	26,138	27,987
Postage and shipping	328	17	345	469	-	469	814	4,359
Banking fees	-	-	-	1,290	1	1,291	1,291	2,875
Miscellaneous	-	168	168	-	-	-	168	-
Total Expenses	<u>\$ 131,793</u>	<u>\$ 229,320</u>	<u>\$ 361,113</u>	<u>\$ 86,686</u>	<u>\$ 20,756</u>	<u>\$ 107,442</u>	<u>\$ 468,555</u>	<u>\$ 423,465</u>

See Independent Auditors' Report

**The National Hemophilia Foundation and Affiliate
Nebraska Chapter**

Statement of Financial Position
December 31, 2022
(With summarized totals at December 31, 2021)

	2022			2021
	Without Donor Restrictions	With Donor Restrictions	Total	Total
ASSETS				
Cash and cash equivalents	\$ 332,237	\$ 1,904	\$ 334,141	\$ 365,935
Grants and other receivables	1,802	-	1,802	500
Prepaid expenses and other assets	1,722	-	1,722	2,440
Security deposits	599	-	599	599
Right-of-use asset, net	64,481	-	64,481	-
	<u>\$ 400,841</u>	<u>\$ 1,904</u>	<u>\$ 402,745</u>	<u>\$ 369,474</u>
LIABILITIES AND NET ASSETS				
Liabilities				
Accounts payable	\$ -	\$ -	\$ -	\$ 311
Deferred support and revenue	4,277	-	4,277	-
Intercompany payable	48,305	-	48,305	59,950
Operating lease liability	64,599	-	64,599	-
Total Liabilities	<u>117,181</u>	<u>-</u>	<u>117,181</u>	<u>60,261</u>
Net Assets				
Without donor restrictions - undesignated	283,660	-	283,660	294,213
With donor restrictions - restricted by purpose or time	<u>-</u>	<u>1,904</u>	<u>1,904</u>	<u>15,000</u>
Total Net Assets	<u>283,660</u>	<u>1,904</u>	<u>285,564</u>	<u>309,213</u>
	<u>\$ 400,841</u>	<u>\$ 1,904</u>	<u>\$ 402,745</u>	<u>\$ 369,474</u>

See Independent Auditors' Report

**The National Hemophilia Foundation and Affiliate
Nebraska Chapter**

Statement of Activities
Year Ended December 31, 2022
(With summarized totals for the year ended December 31, 2021)

	2022			2021
	Without Donor Restrictions	With Donor Restrictions	Total	Total
SUPPORT AND REVENUE				
Special events revenue	\$ 48,319	\$ -	\$ 48,319	\$ 50,957
Contributions and grants	164,616	-	164,616	162,523
Contributions from federal campaign	16,182	-	16,182	11,811
Revenues generated from NHF and chapters	-	-	-	25,700
Investment income	75	-	75	35
Publication income	10,600	-	10,600	20,500
Net assets released from restrictions	<u>13,096</u>	<u>(13,096)</u>	<u>-</u>	<u>-</u>
Total Support and Revenue	<u>252,888</u>	<u>(13,096)</u>	<u>239,792</u>	<u>271,526</u>
EXPENSES				
Program Services				
Health education and training	116,572	-	116,572	93,985
Community services	<u>44,521</u>	<u>-</u>	<u>44,521</u>	<u>48,084</u>
Total Program Services	<u>161,093</u>	<u>-</u>	<u>161,093</u>	<u>142,069</u>
Supporting Services				
Management and general	59,250	-	59,250	61,389
Fundraising	<u>43,098</u>	<u>-</u>	<u>43,098</u>	<u>37,224</u>
Total Supporting Services	<u>102,348</u>	<u>-</u>	<u>102,348</u>	<u>98,613</u>
Total Expenses	<u>263,441</u>	<u>-</u>	<u>263,441</u>	<u>240,682</u>
Change in Net Assets	(10,553)	(13,096)	(23,649)	30,844
NET ASSETS				
Beginning of year	<u>294,213</u>	<u>15,000</u>	<u>309,213</u>	<u>278,369</u>
End of year	<u>\$ 283,660</u>	<u>\$ 1,904</u>	<u>\$ 285,564</u>	<u>\$ 309,213</u>

See Independent Auditors' Report

**The National Hemophilia Foundation and Affiliate
Nebraska Chapter**

**Statement of Functional Expenses
Year Ended December 31, 2022
(With summarized totals for the year ended December 31, 2021)**

	2022						2021	
	Program Services			Supporting Services			Total	Total
	Health Education and Training	Community Services	Total Program Services	Management and General	Fundraising	Total Supporting Services		
Salaries	\$ 58,413	\$ 21,989	\$ 80,402	\$ 25,020	\$ 19,679	\$ 44,699	\$ 125,101	\$ 105,197
Employee benefits and payroll taxes	19,423	9,701	29,124	9,953	10,689	20,642	49,766	51,873
Pension expense	2,998	1,537	4,535	1,563	1,718	3,281	7,816	7,277
Total Salaries and Related Expenses	<u>80,834</u>	<u>33,227</u>	<u>114,061</u>	<u>36,536</u>	<u>32,086</u>	<u>68,622</u>	<u>182,683</u>	<u>164,347</u>
Supplies	4,003	739	4,742	1,454	1,034	2,488	7,230	9,301
Printing	661	188	849	1,953	1,431	3,384	4,233	1,217
Telephone	-	-	-	3,463	-	3,463	3,463	3,677
Occupancy	-	-	-	9,426	-	9,426	9,426	7,302
Equipment rental and maintenance	-	2,605	2,605	-	-	-	2,605	1,548
Travel, conferences and conventions	25,991	5,547	31,538	1,203	7,034	8,237	39,775	34,877
Accounting and auditing	-	-	-	500	-	500	500	500
Consulting and professional fees	3,970	1,045	5,015	-	905	905	5,920	6,295
Membership dues	-	-	-	1,649	-	1,649	1,649	1,741
Awards and grants	912	1,096	2,008	500	-	500	2,508	5,522
Postage and shipping	201	74	275	552	118	670	945	1,646
Banking fees	-	-	-	2,014	490	2,504	2,504	2,709
Total Expenses	<u>\$ 116,572</u>	<u>\$ 44,521</u>	<u>\$ 161,093</u>	<u>\$ 59,250</u>	<u>\$ 43,098</u>	<u>\$ 102,348</u>	<u>\$ 263,441</u>	<u>\$ 240,682</u>

See Independent Auditors' Report

**The National Hemophilia Foundation and Affiliate
West Virginia Chapter**

Statement of Financial Position
December 31, 2022
(With summarized totals at December 31, 2021)

	2022			2021
	Without Donor Restrictions	With Donor Restrictions	Total	Total
ASSETS				
Cash and cash equivalents	\$ 156,764	\$ 129,368	\$ 286,132	\$ 356,637
Grants and other receivables	1,000	-	1,000	5,500
Prepaid expenses and other assets	14,249	-	14,249	7,993
	<u>\$ 172,013</u>	<u>\$ 129,368</u>	<u>\$ 301,381</u>	<u>\$ 370,130</u>
LIABILITIES AND NET ASSETS				
Liabilities				
Deferred support and revenue	\$ 1,000	\$ -	\$ 1,000	\$ 1,000
Intercompany payable	16,026	-	16,026	17,465
Total Liabilities	<u>17,026</u>	<u>-</u>	<u>17,026</u>	<u>18,465</u>
Net Assets				
Without donor restrictions - undesignated	154,987	-	154,987	194,962
With donor restrictions - restricted by purpose or time	<u>-</u>	<u>129,368</u>	<u>129,368</u>	<u>156,703</u>
Total Net Assets	<u>154,987</u>	<u>129,368</u>	<u>284,355</u>	<u>351,665</u>
	<u>\$ 172,013</u>	<u>\$ 129,368</u>	<u>\$ 301,381</u>	<u>\$ 370,130</u>

See Independent Auditors' Report

**The National Hemophilia Foundation and Affiliate
West Virginia Chapter**

Statement of Activities
Year Ended December 31, 2022
(With summarized totals for the year ended December 31, 2021)

	2022			2021
	Without Donor Restrictions	With Donor Restrictions	Total	Total
SUPPORT AND REVENUE				
Special events revenue	\$ 18,272	\$ -	\$ 18,272	\$ 20,143
Contributions and grants	61,430	-	61,430	172,807
Revenues generated from NHF and chapters	6,000	-	6,000	14,521
Contributions from federal campaign	20	-	20	-
Educational/medical literature	10,500	-	10,500	18,572
Net assets released from restrictions	<u>27,335</u>	<u>(27,335)</u>	<u>-</u>	<u>-</u>
Total Support and Revenue	<u>123,557</u>	<u>(27,335)</u>	<u>96,222</u>	<u>226,043</u>
EXPENSES				
Program Services				
Health education and training	49,007	-	49,007	20,990
Community services	<u>47,413</u>	<u>-</u>	<u>47,413</u>	<u>77,294</u>
Total Program Services	<u>96,420</u>	<u>-</u>	<u>96,420</u>	<u>98,284</u>
Supporting Services				
Management and general	39,364	-	39,364	35,641
Fundraising	<u>27,748</u>	<u>-</u>	<u>27,748</u>	<u>10,556</u>
Total Supporting Services	<u>67,112</u>	<u>-</u>	<u>67,112</u>	<u>46,197</u>
Total Expenses	<u>163,532</u>	<u>-</u>	<u>163,532</u>	<u>144,481</u>
Change in Net Assets	(39,975)	(27,335)	(67,310)	81,562
NET ASSETS				
Beginning of year	<u>194,962</u>	<u>156,703</u>	<u>351,665</u>	<u>270,103</u>
End of year	<u>\$ 154,987</u>	<u>\$ 129,368</u>	<u>\$ 284,355</u>	<u>\$ 351,665</u>

See Independent Auditors' Report

**The National Hemophilia Foundation and Affiliate
West Virginia Chapter**

**Statement of Functional Expenses
Year Ended December 31, 2022
(With summarized totals for the Year Ended December 31, 2021)**

	2022						2021	
	Program Services			Supporting Services			Total	Total
	Health Education and Training	Community Services	Total Program Services	Management and General	Fundraising	Total Supporting Services		
Salaries	\$ 12,740	\$ 17,847	\$ 30,587	\$ 20,848	\$ 18,363	\$ 39,211	\$ 69,798	\$ 63,733
Employee benefits and payroll taxes	3,944	5,735	9,679	5,986	5,324	11,310	20,989	25,892
Pension expense	165	244	409	237	218	455	864	904
Total Salaries and Related Expenses	<u>16,849</u>	<u>23,826</u>	<u>40,675</u>	<u>27,071</u>	<u>23,905</u>	<u>50,976</u>	<u>91,651</u>	<u>90,529</u>
Supplies	419	1,020	1,439	1,278	732	2,010	3,449	6,421
Printing	695	1,448	2,143	500	269	769	2,912	2,869
Telephone	-	-	-	3,040	-	3,040	3,040	3,574
Insurance	-	1,306	1,306	-	-	-	1,306	304
Equipment rental and maintenance	2,604	-	2,604	3,439	-	3,439	6,043	3,375
Travel, conferences and conventions	28,236	1,041	29,277	1,406	2,383	3,789	33,066	7,525
Accounting and auditing	-	-	-	500	-	500	500	923
Consulting and professional fees	-	15,250	15,250	-	-	-	15,250	7,027
Membership dues	-	750	750	450	-	450	1,200	2,675
Awards and grants	-	1,674	1,674	250	-	250	1,924	17,168
Postage and shipping	204	1,098	1,302	503	383	886	2,188	1,096
Banking fees	-	-	-	927	76	1,003	1,003	995
Total Expenses	<u>\$ 49,007</u>	<u>\$ 47,413</u>	<u>\$ 96,420</u>	<u>\$ 39,364</u>	<u>\$ 27,748</u>	<u>\$ 67,112</u>	<u>\$ 163,532</u>	<u>\$ 144,481</u>

See Independent Auditors' Report

**The National Hemophilia Foundation and Affiliate
Hawaii Chapter**

Statement of Financial Position
December 31, 2022
(With summarized totals at December 31, 2021)

	2022		2021	
	Without Donor Restrictions	With Donor Restrictions	Total	Total
ASSETS				
Cash and cash equivalents	\$ 360,987	\$ 9,258	\$ 370,245	\$ 480,464
Grants and other receivables	7,500	-	7,500	3,000
Prepaid expenses and other assets	1,691	-	1,691	17,903
	<u>\$ 370,178</u>	<u>\$ 9,258</u>	<u>\$ 379,436</u>	<u>\$ 501,367</u>
LIABILITIES AND NET ASSETS				
Liabilities				
Accounts payable	\$ -	\$ -	\$ -	\$ 61
Deferred support and revenue	2,250	-	2,250	-
Intercompany payable	21,451	-	21,451	57,430
Total Liabilities	<u>23,701</u>	<u>-</u>	<u>23,701</u>	<u>57,491</u>
Net Assets				
Without Donor Restrictions				
Undesignated	346,477	-	346,477	433,294
Board-designated	-	-	-	6,250
Total Net Assets Without Donor Restrictions	<u>346,477</u>	<u>-</u>	<u>346,477</u>	<u>439,544</u>
With Donor Restrictions				
Restricted by purpose or time	-	9,258	9,258	4,332
Total Net Assets	<u>346,477</u>	<u>9,258</u>	<u>355,735</u>	<u>443,876</u>
	<u>\$ 370,178</u>	<u>\$ 9,258</u>	<u>\$ 379,436</u>	<u>\$ 501,367</u>

See Independent Auditors' Report

**The National Hemophilia Foundation and Affiliate
Hawaii Chapter**

Statement of Activities
Year Ended December 31, 2022
(With summarized totals for the year ended December 31, 2021)

	2022			2021
	Without Donor Restrictions	With Donor Restrictions	Total	Total
SUPPORT AND REVENUE				
Special events revenue	\$ 56,127	\$ -	\$ 56,127	\$ 36,528
Contributions and grants	129,840	8,500	138,340	144,279
Revenues generated from NHF and chapters	6,625	-	6,625	21,421
Educational/medical literature	6,000	-	6,000	16,250
Net assets released from restrictions	3,574	(3,574)	-	-
Total Support and Revenue	<u>202,166</u>	<u>4,926</u>	<u>207,092</u>	<u>218,478</u>
EXPENSES				
Program Services				
Health education and training	86,240	-	86,240	33,186
Community services	116,345	-	116,345	71,654
Total Program Services	<u>202,585</u>	<u>-</u>	<u>202,585</u>	<u>104,840</u>
Supporting Services				
Management and general	35,908	-	35,908	22,222
Fundraising	56,740	-	56,740	20,162
Total Supporting Services	<u>92,648</u>	<u>-</u>	<u>92,648</u>	<u>42,384</u>
Total Expenses	<u>295,233</u>	<u>-</u>	<u>295,233</u>	<u>147,224</u>
Change in Net Assets	(93,067)	4,926	(88,141)	71,254
NET ASSETS				
Beginning of year	<u>439,544</u>	<u>4,332</u>	<u>443,876</u>	<u>372,622</u>
End of year	<u>\$ 346,477</u>	<u>\$ 9,258</u>	<u>\$ 355,735</u>	<u>\$ 443,876</u>

See Independent Auditors' Report

**The National Hemophilia Foundation and Affiliate
Hawaii Chapter**

**Statement of Functional Expenses
Year Ended December 31, 2022
(With summarized totals for the Year Ended December 31, 2021)**

	2022						2021	
	Program Services			Supporting Services			Total	Total
	Health Education and Training	Community Services	Total Program Services	Management and General	Fundraising	Total Supporting Services		
Salaries	\$ 26,502	\$ 59,816	\$ 86,318	\$ 15,012	\$ 25,973	\$ 40,985	\$ 127,303	\$ 71,328
Employee benefits and payroll taxes	9,274	20,312	29,586	5,046	8,914	13,960	43,546	31,735
Pension expense	389	727	1,116	170	339	509	1,625	389
Total Salaries and Related Expenses	<u>36,165</u>	<u>80,855</u>	<u>117,020</u>	<u>20,228</u>	<u>35,226</u>	<u>55,454</u>	<u>172,474</u>	<u>103,452</u>
Supplies	4,076	2,326	6,402	3,260	1,732	4,992	11,394	7,874
Printing	-	-	-	1,416	319	1,735	1,735	2,361
Telephone	-	-	-	2,075	-	2,075	2,075	2,027
Insurance	-	587	587	-	-	-	587	-
Equipment rental and maintenance	-	2,173	2,173	1,452	-	1,452	3,625	2,210
Travel, conferences and conventions	45,999	27,536	73,535	4,231	17,297	21,528	95,063	17,052
Accounting and auditing	-	-	-	500	-	500	500	700
Consulting and professional fees	-	1,750	1,750	-	681	681	2,431	-
Membership dues	-	-	-	726	-	726	726	2,050
Awards and grants	-	1,118	1,118	500	-	500	1,618	5,654
Postage and shipping	-	-	-	410	42	452	452	1,546
Banking fees	-	-	-	1,110	1,443	2,553	2,553	2,298
Total Expenses	<u>\$ 86,240</u>	<u>\$ 116,345</u>	<u>\$ 202,585</u>	<u>\$ 35,908</u>	<u>\$ 56,740</u>	<u>\$ 92,648</u>	<u>\$ 295,233</u>	<u>\$ 147,224</u>

See Independent Auditors' Report

Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With Government Auditing Standards

Independent Auditors' Report

**To the Board of Directors of
The National Hemophilia Foundation and Affiliate**

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the consolidated financial statements of The National Hemophilia Foundation and Affiliate, (collectively, the "Foundation"), which comprise the consolidated statement of financial position as of December 31, 2022, and the related consolidated statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated June 16, 2023.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered the Foundation's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Foundation's internal control. Accordingly, we do not express an opinion on the effectiveness of the Foundation's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. *A material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. *A significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that have not been identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Foundation's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the consolidated financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

PKF O'Connor Davies, LLP

June 16, 2023